Related Experiment Videos
[Long-term obsidan therapy of ischemic heart disease patients at high risk for sudden death]
Insights
Long-term obsidan treatment effectively reduced heart rate and blood pressure in ischaemic heart disease (IHD) patients. This cardiac medication also improved angina pectoris symptoms and showed a trend towards reducing ventricular extrasystoles.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Ischaemic heart disease (IHD) poses a high risk of sudden cardiac death.
- Ventricular extrasystole is a common complication in IHD patients.
Purpose:
- To investigate the efficacy of long-term obsidan treatment in managing IHD patients at high risk of sudden death.
- To assess the impact of obsidan on heart rate, blood pressure, and angina pectoris.
Summary:
- A study involving 175 IHD patients with significant ventricular extrasystole compared long-term obsidan treatment with a control group.
- Obsidan treatment led to a significant average heart rate reduction of 19.2% and a 11% decrease in systolic and diastolic blood pressure.
- The treated group experienced a 16% improvement in angina pectoris, compared to 6% in the control group, and a trend towards reduced severe ventricular extrasystoles.
Impact:
- Long-term obsidan therapy demonstrates significant benefits in managing cardiovascular parameters and symptoms in high-risk IHD patients.
- Obsidan may be a valuable therapeutic option for reducing sudden cardiac death risk in selected IHD populations.
- Further research could explore the long-term safety and efficacy of obsidan in diverse IHD patient groups.
Abstract:
To study the possibilities of long-term obsidan treatment of ischaemic heart disease (IHD) patients with high risk of sudden death 865 men aged 35-39 years with IHD were examined twice. After the examination including a 24-hour ECG monitoring and the tread-mill test 175 men were selected with grade 2 and over of ventricular extrasystole without contraindications to prolonged treatment with obsidan. The patients were divided into two groups: the treated group (with obsidan) and a control group without active treatment. The treatment with obsidan began with 40 mg/day, the dose being gradually increased. The daily dose was assessed as adequate for stable decrease of the heart rate by 15-20%. As a result of treatment it was possible to decrease the heart rate by 19.2%, on the average, in the control group it was 2.8%. Systolic and diastolic arterial pressure decreased in the first group by 11%, in the control group it rose by 4%. Improvement in angina pectoris course in the first group rose by 16%, in the other group only by 6%. A certain tendency has been recorded in the group of obsidan treated patients to lowering the number of those with 4-5 grades of ventricular extra-systole.